DBV Technologies | DBVT - Net Income


DBV Technologies reported $-47.6M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amarin USD -1.22M 6.51M Dec/2025
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
DBV Technologies USD -47.6M 2.77M Mar/2026
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026